Skip to content

Epidemiological Screening of IL10RA Mutation Rate in China

Epidemiological Screening of p.R101W and p.T179T IL10RA Mutation Rates in Henan Province, China

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03097731
Acronym
Yes
Enrollment
0
Registered
2017-03-31
Start date
2019-07-01
Completion date
2021-07-01
Last updated
2019-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System Disease

Keywords

interleukin-10, inflammatory bowel disease

Brief summary

The presentation of IBD in early childhood is uncommon and the monogenetic defects, especially IL-10 signaling pathway play a key role in very early onset inflammatory bowel disease (VEO-IBD). IL-10 or IL-10R deficiency associated VEO-IBD is considered a rare disorder. To date, there were about 60 cases were reported all over the word. But in our Chinese VEO-IBD Collaboration Group, 42 patients with biallelic mutations affecting IL10R genes were identified from 93 VEO-IBD patients, and the mutation sites are highly concentrated, including 83.9% (26/31) with p.R101W and 55% p.T179T (17/31) mutation, and the proportion of patients from Henan( A province of China) is higher. So we speculate that IL-10RA mutation may not be very rare, and the frequency of heterozygote subjects might be higher than suspected.

Detailed description

1. The mutation rates of p.R101W and p.T179T IL10RA in Henan newborn. 2. Is there any clinical symptoms in children with IL-10RA-deficient? and the onset of the symptoms. 3. Whether the intestinal permeability is normal in heterozygote subjects.

Interventions

None listed

Sponsors

Children's Hospital of Fudan University
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
24 Hours to 28 Days

Inclusion criteria

* In the study period, all newborns in the selected hospita

Exclusion criteria

* Children whose guardian refused to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
The mutation rate of IL-10RA in chineseFrom birth to 3 years oldAll present mutations in IL-10RA

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026